INS and cancer: Some clinical studies support the notion that the glucose lowering benefits of insulin override its potential mitogenic effects and reduce cancer risk (Yang et al, 2010), whereas a meta-analysis concluded that intensive glycemic control may not significantly influence cancer incidence in T2D (Johnson & Bowker, 2011).